Navidea Biopharmaceuticals to Present at LD Micro 10th Annual Main Event
November 21 2017 - 8:00AM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company
focused on the development of precision immunodiagnostic agents and
immunotherapeutics, today announced it will present at the LD
Micro 10th Annual Main Event in Los Angeles, CA on December 5-7,
2017. Jed Latkin, Chief Financial Officer and Chief Operating
Officer of Navidea, will be giving a presentation and meeting with
investors throughout the conference.
Event:
LD Micro 10th Annual Main Event
Date:
Thursday, December 7th, 2017
Time:
9:30am PT (Pacific Time)
Location:
Luxe Sunset Boulevard Hotel, Los Angeles, CA
For investors attending the LD Micro Conference, please contact
Navidea Investor Relations to schedule a meeting with Navidea
management
at tpatel@edisongroup.com or ir@navidea.com.
The presentation will be webcast live and remain available for
90 days following the presentation. To access the webcast, please
visit the Events tab of the Investor Relations section of the
Navidea website at www.navidea.com.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
ManoceptTM platform to enhance patient care by identifying the
sites and pathways of disease and enable better diagnostic
accuracy, clinical decision-making, and targeted treatment.
Navidea’s Manocept platform is predicated on the ability to
specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the
molecular backbone of Tc 99m tilmanocept, the first product
developed and commercialized by Navidea based on the platform. The
development activities of the Manocept immunotherapeutic platform
are being conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver
superior growth and shareholder return by bringing to market novel
products and advancing the Company’s pipeline through global
partnering and commercialization efforts.
For more information, please visit www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171121005358/en/
Navidea Biopharmaceuticals, Inc.Jed Latkin,
614-551-3416CFO/COOjlatkin@navidea.comorEdison AdvisorsTirth Patel,
646-653-7035tpatel@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024